These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 24951330

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
    Wang Y, Sun X, Yang D, Guo Z, Fan X, Nie M, Zhang F, Liu Y, Li Y, Wang Y, Gong P, Liu Y.
    Bioorg Med Chem; 2016 Nov 01; 24(21):5646-5661. PubMed ID: 27663548
    [Abstract] [Full Text] [Related]

  • 3. Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
    Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.
    Bioorg Med Chem Lett; 2009 Jan 15; 19(2):462-8. PubMed ID: 19046881
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.
    Xue T, Ding S, Guo B, Zhou Y, Sun P, Wang H, Chu W, Gong G, Wang Y, Chen X, Yang Y.
    J Med Chem; 2014 Sep 25; 57(18):7770-91. PubMed ID: 25179681
    [Abstract] [Full Text] [Related]

  • 6. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.
    J Med Chem; 2007 Nov 01; 50(22):5339-56. PubMed ID: 17914785
    [Abstract] [Full Text] [Related]

  • 7. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.
    Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC.
    Thromb Haemost; 2009 Apr 01; 101(4):780-2. PubMed ID: 19350128
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PY.
    Bioorg Med Chem Lett; 2006 Aug 01; 16(15):4141-7. PubMed ID: 16730984
    [Abstract] [Full Text] [Related]

  • 10. Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.
    Frost C, Garonzik S, Shenker A, Barrett YC, LaCreta F.
    Clin Pharmacol Drug Dev; 2021 Sep 01; 10(9):974-984. PubMed ID: 34342172
    [Abstract] [Full Text] [Related]

  • 11. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
    Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR.
    J Enzyme Inhib Med Chem; 2011 Aug 01; 26(4):514-26. PubMed ID: 21171894
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats.
    Myers JA, Wittenburg LA, Olver CS, Martinez CM, Bright JM.
    Am J Vet Res; 2015 Aug 01; 76(8):732-8. PubMed ID: 26207972
    [Abstract] [Full Text] [Related]

  • 16. Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.
    Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY.
    Bioorg Med Chem Lett; 2007 Mar 01; 17(5):1432-7. PubMed ID: 17174550
    [Abstract] [Full Text] [Related]

  • 17. Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
    Corte JR, Fang T, Pinto DJ, Han W, Hu Z, Jiang XJ, Li YL, Gauuan JF, Hadden M, Orton D, Rendina AR, Luettgen JM, Wong PC, He K, Morin PE, Chang CH, Cheney DL, Knabb RM, Wexler RR, Lam PY.
    Bioorg Med Chem Lett; 2008 May 01; 18(9):2845-9. PubMed ID: 18424044
    [Abstract] [Full Text] [Related]

  • 18. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
    Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):1795-8. PubMed ID: 16434195
    [Abstract] [Full Text] [Related]

  • 19. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC, Wang Z, Frost C, Shenker A.
    Thromb Haemost; 2010 Dec 01; 104(6):1263-71. PubMed ID: 20978714
    [Abstract] [Full Text] [Related]

  • 20. Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillation.
    Hohnloser SH.
    Eur Heart J; 2014 Jul 21; 35(28):1828-9. PubMed ID: 25184177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.